Pfizer Centers for Therapeutic Innovation, Pfizer Inc., New York, NY, USA.
Pfizer Centers for Therapeutic Innovation, Pfizer Inc., New York, NY, USA.
Trends Pharmacol Sci. 2022 Oct;43(10):820-837. doi: 10.1016/j.tips.2022.07.001. Epub 2022 Aug 23.
Biomolecular condensates organize cellular functions in the absence of membranes. These membraneless organelles can form through liquid-liquid phase separation coalescing RNA and proteins into well-defined, yet dynamic, structures distinct from the surrounding cellular milieu. Numerous physiological and disease-causing processes link to biomolecular condensates, which could impact drug discovery in several ways. First, disruption of pathological condensates seeded by mutated proteins or RNAs may provide new opportunities to treat disease. Second, condensates may be leveraged to tackle difficult-to-drug targets lacking binding pockets whose function depends on phase separation. Third, condensate-resident small molecules and RNA therapeutics may display unexpected pharmacology. We discuss the potential impact of phase separation on drug discovery and RNA therapeutics, leveraging concrete examples, towards novel clinical opportunities.
生物分子凝聚物在没有膜的情况下组织细胞功能。这些无膜细胞器可以通过液-液相分离形成,将 RNA 和蛋白质凝聚成明确但动态的结构,与周围的细胞环境明显不同。许多生理和致病过程与生物分子凝聚物有关,这可能会以多种方式影响药物发现。首先,破坏由突变蛋白或 RNA 引发的病理性凝聚物可能为治疗疾病提供新的机会。其次,可以利用凝聚物来解决缺乏结合口袋的难以成药的靶标,这些靶标的功能依赖于相分离。第三,凝聚物中存在的小分子和 RNA 疗法可能会表现出意想不到的药理学。我们讨论了相分离对药物发现和 RNA 疗法的潜在影响,利用具体实例探讨了新的临床机会。